Empower your strategies with our Net Present Value Model: Sanofi’s Frexalimab report and make more profitable business decisions.
Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development.
Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.

Sanofi’s Frexalimab Drug Details:
Frexalimab (INX-021) is under development for the treatment of autoimmune diseases including relapsing multiple sclerosis, relapsing remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), active systemic lupus erythematosus (SLE), focal segmental glomerulosclerosis (FSGS) and type 1 diabetes. It is administered through intravenous and subcutaneous route. The therapeutic candidate is a re-engineered antagonist antibody that acts on CD40.It was under development for primary Sjogren’s syndrome disease.
Report Coverage
GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.
Scope of Report
- Drug Name
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
- Patent law
- Known and Projected regulatory approval processes
- Cash flows
- Potential applicable patients
- Drug margins
- Company expenses
- Pricing estimates
Reasons to buy
- Obtain a better understanding of the quantitative value of Net Present Value Model: Sanofi’s Frexalimab.
- Access another data source to use in the valuation of Net Present Value Model: Sanofi’s Frexalimab.
- Create or support internal NPV models to improve accuracy.
- Understand a drug’s expected profit, considering revenue and cost forecasts leveraging public and proprietary data sets.







